Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | GRPR | P30550 | 2/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.55 |
| ▸ | GLP1R | P43220 | 4/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637763 | 0.94 | RXFP1 (0.61) | RXFP1GRPRNPBWR1IL23RGLP1R | |
| SCHEMBL30874393 | 0.94 | RXFP1 (0.60) | RXFP1GRPRNPBWR1IL23RGLP1R | |
| SCHEMBL30598172 | 0.93 | RXFP1 (0.63) | RXFP1NPBWR1IL23RGLP1RECE1 | |
| SCHEMBL30578571 | 0.92 | RXFP1 (0.58) | RXFP1GRPRNPBWR1IL23RGLP1R | |
| SCHEMBL30242111 | 0.92 | IL23R (0.59) | RXFP1NPBWR1IL23RPCSK9 | |
| SCHEMBL31453816 | 0.92 | RXFP1 (0.65) | RXFP1NPBWR1IL23RGLP1RECE1 | |
| SCHEMBL3113818 | 0.91 | RXFP1 (0.54) | RXFP1GRPRNPBWR1IL23RGLP1R | |
| SCHEMBL30690354 | 0.90 | RXFP1 (0.63) | RXFP1GRPRIL23RGLP1RECE1 | |
| SCHEMBL29443912 | 0.89 | RXFP1 (0.63) | RXFP1GRPRIL23RGLP1RECE1 | |
| SCHEMBL30262147 | 0.89 | IL23R (0.68) | NPBWR1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | GLP1R, IAPP, GCG | RXFP1 271/4885GRPR 36/4885NPBWR1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.